7 Remyelination Articles You Must Read

1. CONy16: MS Researchers Question Possible Long-term Benefits of Remyelination Therapies

“Multiple sclerosis was a main focus at the four-day 10th World Congress on Controversies in Neurology (CONy), in Lisbon, Portugal, that concluded on March 20. Among the topics of debate was demyelination as the disease’s main pathogenic precursor and the clinical potential of remyelination.”

2. Fluorosamine Seen to Boost Remyelination in MS Mouse Model by Blocking Scarring Molecules

“A substance called fluorosamine was seen to boost remyelination in mice by preventing the synthesis of chondroitin sulfate proteoglycans and by promoting oligodendrocyte function. The findings showed that targeting molecules that block remyelination may be a promising therapeutic approach in multiple sclerosis (MS).”

3. Antihistamine Aids in Reversing Visual Damage in MS Patients and Appears to Have Remyelination Properties, AAN Presentation Reports

“A Phase 2 clinical trial testing the efficacy of a common antihistamine, clemastine fumarate, to treat optic nerve damage in people with multiple sclerosis (MS) found the drug able to slightly reverse damage to their visual system.”

4. Fingolimod (Gilenya) Seen to Promote Peripheral Nerve Regeneration in Mice, Aiding Remyelination

“Fingolimod (Gilenya), a drug approved for patients with relapsing-remitting multiple sclerosis (RRMS) to prevent neuroinflammation, may also help these patients by directly enhancing nerve regeneration and increasing myelination in a way that is partly independent of its anti-inflammatory properties.”

5. Potential Remyelination Therapy for MS, NDC-1308, Advancing in Preclinical Studies

“As Multiple Sclerosis News Today reported in mid-July, Endece Neural was issued an additional U.S. patent for its lead investigational product,NDC-1308. The drug is under development to repair the myelin sheath damaged in multiple sclerosis (MS), a major causing disease progression and increasing disability.”

6. Endece Granted New U.S. Patent for NDC-1308, Therapy to Induce Remyelination in MS

“Endece was recently issued an additional U.S. patent for its lead investigational product, NDC-1308, being developed to induce remyelination in patients with multiple sclerosis (MS) and prevent disease progression.”

7. Remyelination Studies Abound, But How About a Workable Therapy?

“Remyelination at the moment is the buzzword to beat all buzzwords in the world of research into, and treatment for, the vicious disease that is multiple sclerosis.”

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.